METASTATIC SOLID TUMORS: PHASE 1 (ESCALATION): PVRIG+PD-1: CPG-01-001

A Phase 1a/1b study of COM701 as monotherapy and in combination with an anti-PD-1 antibody in subjects with advanced solid tumors.

Title
Compugen CPG-01-001 (Solid Tumors)
Study Title

A Phase 1a/1b study of COM701 as monotherapy and in combination with an anti-PD-1 antibody in subjects with advanced solid tumors.

Site Link
Malignancy
Ovarian, uterine, endometrial, breast, TNBC, lung, colon, CRC, NSCLC, head and neck, SCCHN, gastric, stomach, kidney, renal, RCC, bladder, transitional cell,
Stage
Disease Setting
Metastatic/Palliative
Line Of Therapy
Late line
Investigational Agent
COM-701, PD(L)-1 antibody
Drug Class
PVRIG monoclonal antibody, PD(L)-1 antibody
PI
Dan Vaena, MD
Sponsor
Compugen
Phase
Status
Key Eligibility Criteria
Key Eligibility Criteria Details
  • Histologically or cytologically confirmed, metastatic solid malignancy
  • Has exhausted all available standard therapy or not a candidate for standard therapy
  • ECOG PS 0-1
  • Prior PD-1/PD-L1 allowed
  • No other malignancy within 2 years prior
  • No active autoimmune disease requiring systemic therapy within last 2 years
  • No chronic steroids or immunosuppressants.
Objective

Primary- MTD, PK profile

Secondary- Immunogenicity, preliminary antitumor activity

Assessment Frequency
_
Assessment Frequency 2
_



Assessment Frequency Link
Path
Dosing Frequency
Control Agents
Study Protocol
Randomized
No
X